PNC Financial Services Group’s Soleno Therapeutics SLNO Stock Holding History

PNC Financial Services Group’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50	Closed	-$1.67K	–	5338
2026 Q1	$1.67K	Buy	50 +1	+2%	+$39	﹤0.01%	4637
2025 Q4	$2.27K	Sell	49 -2,951	-98%	-$162K	﹤0.01%	4496
2025 Q3	$203K	Sell	3,000 -1,400	-32%	-$104K	﹤0.01%	2293
2025 Q2	$369K	Buy	4,400 +40	+0.9%	+$2.99K	﹤0.01%	1777
2025 Q1	$312K	Buy	4,360 +720	+20%	+$35.1K	﹤0.01%	1874
2024 Q4	$164K	Buy	3,640 +140	+4%	+$7.25K	﹤0.01%	2355
2024 Q3	$177K	Buy	+3,500	New	+$168K	﹤0.01%	2285

PNC Financial Services Group's SLNO Position: Q2 2026 in Review

PNC Financial Services Group sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 50 shares — an estimated $1.67K sold.

PNC Financial Services Group first reported a position in SLNO in Q3 2024 and held it in 7 quarters. The position peaked at $369K in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

PNC Financial Services Group reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
PNC Financial Services Group sold 50 Soleno Therapeutics shares in Q2 2026, an estimated $1.67K.
PNC Financial Services Group first reported a position in Soleno Therapeutics in Q3 2024 and held it in 7 quarters.
PNC Financial Services Group's Soleno Therapeutics position peaked at $369K in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.